Intravenous opioid drug abuse as an independent risk factor for supraglottic squamous cell carcinoma—A case‐control study

Shoffel‐Havakuk, Hagit; Cohen, Oded; Slavin, Moran; Haimovich, Yaara; Halperin, Doron; Lahav, Yonatan

doi:10.1111/coa.12990

Cited by 11 publications

(13 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our findings of an increased risk of HNSCC are in agreement with those of five prior case‐control studies 6,8‐11 . The only study that differed was a cross‐sectional study of 44 laryngeal cancers.…”

Section: Discussionsupporting

confidence: 91%

“…Our findings of an increased risk of HNSCC are in agreement with those of five prior case-control studies. 6,[8][9][10][11] The only study that differed was a cross-sectional study of 44 laryngeal cancers. It showed no association of opium dependency and the pattern of laryngeal anatomic regions.…”

Section: Discussionmentioning

confidence: 99%

“…A few case‐control studies have found strong associations between the use of opium and the risk of laryngeal cancer 6‐10 . The risk of supraglottic laryngeal cancer was also associated with a prescription of intravenous opioid in a case‐control study 11 . Likewise, preliminary results from the Golestan cohort study also showed an increased risk of death due to laryngeal cancer in opium users 12 .…”

Section: Introductionmentioning

confidence: 92%

“…[6][7][8][9][10] The risk of supraglottic laryngeal cancer was also associated with a prescription of intravenous opioid in a case-control study. 11 Likewise, preliminary results from the Golestan cohort study also showed an increased risk of death due to laryngeal cancer in opium users. 12 Consistent with these findings, an ecological study in Iran showed a correlation between higher opium use and higher incidence rates of laryngeal cancer.…”

Section: Introductionmentioning

confidence: 96%

See 3 more Smart Citations

Opium use and the risk of head and neck squamous cell carcinoma

Mohebbi

Hadji

Rashidian

et al. 2020

Intl Journal of Cancer

View full text Add to dashboard Cite

Scant evidence exists to support the association of opium use with head and neck cancer, limited to the larynx and oral cavity. In a multicenter case‐control study—Iran Opium and Cancer study, we recruited 633 cases of head and neck squamous cell carcinoma (HNSCC) (254 lip and oral cavity, 54 pharynx, 327 larynx and 28 other subsites within the head and neck) and 3065 frequency‐matched controls from April 2016 to April 2019. Odds ratios (ORs) for opium use and 95% confidence intervals (95% CIs) were obtained using mixed‐effects logistic regression because of heterogeneity among centers. The adjusted OR (95% CI) for regular opium use was 3.76 (2.96‐4.79) for all HNSCC combined. Strong dose‐response effects were observed by frequency or amount of use, and duration of use. Regular opium uses significantly increased the risk of HNSCC of the pharynx, larynx and other subsites within the head and neck with OR (95% CI) of 2.90 (1.40‐6.02), 6.55 (4.69‐9.13) and 5.95 (2.41‐14.71), respectively. The observed associations were significant even among never tobacco smokers (including cigarette and water‐pipe smoking). Moreover, by the multiplicative interaction scale, the effect of opium use could be varied by cigarette smoking on HNSCC, 8.16 (6.20‐10.74). For the first time, the current study showed opium users have an increased risk of several anatomic subsites of HNSCC.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 92%

Section: Introductionmentioning

confidence: 96%

See 2 more Smart Citations

Opium use and the risk of head and neck squamous cell carcinoma

Mohebbi

Hadji

Rashidian

et al. 2020

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…Another study conducted in Tehran, Iran, also showed that after controlling the effect of smoking, O and D use increased the risk of laryngeal cancer about 6 times (95% CI:1.10-33.23) (Bakhshaee et al, 2017). In a recent study, in Israel a significant relation was observed between IV (intravenous) O and D use and Supraglottic Squamous Cell Carcinoma and the odds ratio for patients with an IVDA history to have SG-SCC relative to G-SCC was 10.84 (95% CI: 1.3-89.4) (Shoffel-Havakuk et al, 2017). Another study showed the odd ratio between opium use and the risk of oral cancers (tongue, palate, and buccal), to be 4.0 (95% CI: 1.2-13.6) (Razmpa et al, 2014).…”

Section: Discussionmentioning

confidence: 96%

Opium Use and Head and Neck Cancers: A Matched Case-Control Study in Iran

Alizadeh

Tahami

Khanjani

et al. 2020

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

Background: Head and Neck (H and N) cancers include malignant tumors of the nasal cavity, pharynx, paranasal sinuses, oral cavity, larynx and salivary glands. Opium use might be related to these cancers. The aim of this study was to investigate the relation between Opium and its Derivatives (O and D) use and the incidence of H and N cancers. Methods: In this case-control study conducted in Kerman, 140 patients with H and N cancers and 280 healthy controls (matched for age, gender, and place of residence) were included. Information about their use of O and D, cigarette smoking, alcohol and diet were collected using a structured questionnaire. Conditional logistic regression was used to investigate the relation between variables. Results: The use of opioids was associated with an increased risk of HandN cancers (Adjusted OR: 8.13; CI: 4.08-16.2). A significant dose-response relation between O and D use was observed, with high use Adjusted OR=8.91; 95% CI: 4.03-19.65 and low use Adjusted OR=6.52; 95% CI: 3.18-13.36. This dose-response association was stronger in patients with laryngeal cancer and opioids use, with high use Adjusted OR = 11.17; 95% CI=4.48-28.09 and low use Adjusted OR = 9.46; 95% CI= 3.97-22.52. Conclusion: The results show that opium use can be considered as an important risk factor for H and N cancers. Also in Iran, opium seems to play a more important role than cigarette smoking.

show abstract

Low doses of methylnaltrexone inhibits head and neck squamous cell carcinoma growth in vitro and in vivo by acting on the mu‐opioid receptor

Görür

Patiño

Corrales

et al. 2021

Journal Cellular Physiology

View full text Add to dashboard Cite

The Mu-opioid receptor (MOR) has been implicated in tumorigenesis and metastasis. Methylnaltrexone (MNTX), an antagonist of MOR, has shown to inhibit tumor growth and metastasis in lung cancer cell lines. The effect of MNTX on other cell lines such as head and neck squamous cell carcinoma (HNSCC) has not been investigated. We measured the expression and activity of the receptor in different HNSCC cell lines.Then, we evaluated the impact of modulating the expression MOR and the effect of MNTX on the proliferation, clonogenic activity, invasion, and migration of two HNSCC (FaDu and MDA686Tu) cell lines expressing MOR and one cell line (UMSCC47) not expressing the receptor. We also evaluated the impact of MNTX on tumor growth and metastasis formation in vivo. Activation of the receptor with [D-Ala2,N-Me-Phe4, Gly5ol] (DAMGO) caused a significant reduction in cyclic adenosine monophosphate levels in FaDu cells. Knockdown of MOR inhibited in vitro aggressive cell behaviors on FaDu and MDA686Tu cells and correlated with a reduction in markers of epithelial-mesenchymal transition. In vitro studies showed that MNTX strongly inhibited the proliferation, clonogenic activity, invasion, and migration of FaDu and MDA686Tu cells but has no effect on UMSCC47 cells. In vivo experiments demonstrated that MNTX suppresses tumor growth in HNSCC cell tumor-bearing mice. Our studies indicate that MOR could be considered as a therapeutic target to treat HNSCC.

show abstract

Intravenous opioid drug abuse as an independent risk factor for supraglottic squamous cell carcinoma—A case‐control study

Abstract: Intravenous opioid drug abuse represents an independent risk factor for SG-SCC. The pathogenesis should be investigated not just as a risk factor, as opioids are commonly used for pain management in oncologic patients.

Cited by 11 publications

References 30 publications

Opium use and the risk of head and neck squamous cell carcinoma

Opium use and the risk of head and neck squamous cell carcinoma

Opium Use and Head and Neck Cancers: A Matched Case-Control Study in Iran

Low doses of methylnaltrexone inhibits head and neck squamous cell carcinoma growth in vitro and in vivo by acting on the mu‐opioid receptor

Contact Info

Product

Resources

About